Search Results

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company based in Japan, announced that its board of directors has approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, North Carolina.

Five years ago, Kyowa Kirin set out to expand its North America operations, adding new employees and capabilities at a rapid pace. The Human Resources team ensures employee input is central to managing that growth and nurturing a culture to support it

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.

Kyowa Kirin’s dealmaking continued on Wednesday when BridgeBio Pharma granted the Japanese company an exclusive license to develop and commercialize infigratinib.

Kyowa Kirin, Inc. will announce findings from an updated systematic literature review (SLR) and meta-analysis comparing the safety of NOURIANZ® (istradefylline) in relation to other levodopa adjunctive therapies for patients with Parkinson’s Disease (PD).

Kyowa Kirin Co., Ltd. a Japan-based global specialty pharmaceutical company discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc, a global gene therapy leader, announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics.